U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,113.87
    -4,688.77 (-7.97%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Video: Cronos Group Exec Chairman On Cultured Cannabinoids And... Marlboro Greens?

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Benzinga’s Cannabis Insider is a live show for cannabis investors.
On Tuesday’s show, hosts Patrick Lane and Javier Hasse discussed cannabinoids innovation with Mike Gorenstein, The Cronos Group (NASDAQ: CRON) executive chairman.
Lane and Hasse also had time to look into the following publicly-traded companies:

  • Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF)

  • Harvest Health & Recreation Inc (OTC: HRVSF)

  • Gage Growth Corp (CSE: GAGE)

  • Khiron Life Sciences (TSE: KHRN)

  • HEXO (TSE: HEXO)

Meet The Hosts:
Patrick Lane: https://twitter.com/patricklanebz

Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.